People · Operator
Named in public records as an officer, director or promoter · active 2017–2020 · Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. | — | Pharma | Series D+ | $144.7M | $4.2B | 2020 |
| Maverick Therapeutics Inc. | — | Biotechnology | Series C | $56.0M | $2.3B | 2017 |
Lori Kunkel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lori Kunkel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| LEON CHEN | 1 | 15 |
| Luke Evnin | 1 | 12 |
| David Goeddel | 1 | 10 |
| Julia Gregory | 1 | 3 |
| Robert Tjian | 1 | 3 |
| Bard Geesaman | 1 | 3 |
| Jeff Tong | 1 | 2 |
| Mark Goldsmith | 1 | 2 |
| Arthur T Sands | 1 | 2 |
| David Lacey | 1 | 2 |
| Arthur Sands | 1 | 1 |
| Hans Peter Gerber | 1 | 1 |
| Christine Ring | 1 | 1 |
| Hans Van Houte | 1 | 1 |
| Dan Hicklin | 1 | 1 |
| Christopher Arendt | 1 | 1 |
| Timothy Kutzkey | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.